Clinical Trials Logo

Clinical Trial Summary

This is a phase 2, double-blind study to assess the efficacy, safety, tolerability, and pharmacokinetics of NBI-827104 when administered once daily for 13 weeks in pediatric subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04625101
Study type Interventional
Source Neurocrine Biosciences
Contact
Status Completed
Phase Phase 2
Start date April 26, 2021
Completion date October 11, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT01858285 - Genetics of Epilepsy and Related Disorders
Recruiting NCT04802135 - Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy
Terminated NCT03955432 - Long-term Cardiac Monitoring in Epilepsy N/A
Recruiting NCT05722990 - Genetic Investigations in Children With Developmental and Epileptic Encephalopathies in Ho Chi Minh City, Vietnam
Enrolling by invitation NCT05301894 - Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Phase 2
Recruiting NCT02603991 - Prospective Cohort Study on the Efficacy of Vagus Nerve Stimulation for Children and Adolescents With Epilepsy(PVNS-CAE) N/A
Recruiting NCT04496310 - Tele-epic (Telemedicine for Epilepsy Care) N/A
Recruiting NCT03934268 - A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy
Active, not recruiting NCT03024827 - Cannabidiol in Children With Refractory Epileptic Encephalopathy Phase 1
Active, not recruiting NCT03936777 - A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome Phase 3